OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA

Sun Pharmaceutical Industries Ltd

SUNPHARMA · Pharmaceuticals · India

Profile
TickerSUNPHARMA
RICSUN.NS
ISININE044A01036
IssuerSun Pharmaceutical Industries Ltd
SectorHealth Care
IndustryPharmaceuticals
Sub-industryPharmaceuticals
HeadquartersMumbai, India
Country of issuerIndia
Founded1993-03-01
Employees
Total share float1,064,956,363
Holders (C/S)729,019
AuditorS R B C & CO LLP
CEO / managementMr. Dilip Shantilal Shanghvi
Business Description

Sun Pharmaceutical Industries Limited is an India-based specialty generic pharmaceutical company with a presence in specialty, generics and consumer healthcare products. The Company's global specialty portfolio spans products in dermatology, ophthalmology, and onco-dermatologym, among others. The Company manufactures and markets a large basket of pharmaceutical formulations across chronic and acute therapies, including generic, branded generics, specialty and complex products, over-the-counter (OTC), antiretrovirals (ARV), Active Pharmaceutical Ingredients (API), and intermediates. Its portfolio spans multiple dosage forms, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids. Its marketed specialty portfolio includes Ilumya/ Ilumetri, Winlevi, Levulan Kerastick + BLU-U, Absorica LD, Odomzo, Cequa, Bromsite, Xelpros, and others. Its portfolio also includes UNLOXCYTTM, an anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma.

ESG · Risk Indicators
Controversies score25.5
Governance pillar63.6
Social pillar84.4
Insider trading score
Industry · Pharmaceuticals
Signals to watch
Geopolitical drivers
  • drug_pricing_legislation_us_ira
  • country_reimbursement_regimes
  • manufacturing_geo_concentration
  • tariffs_on_pharma_imports
Industry KPIs
Full Analysis Pending

Detailed financial analysis, valuation snapshot, multi-period history, and AI narrative are pending — generated when this company is included in the next analysis batch. Profile data above is point-in-time as of 2026-04-30.